Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.4701 | 1.87% | 25.6001 | 25.75 | 25.23 | 25.24 | 40,850,602 | 01:00:00 |
From Nov 2023 to Nov 2024
By Will Feuer
Pfizer said revenue could fall next year, weighed down by a continued slowdown in demand for the pharmaceutical company's Covid-19 vaccine and related products.
The company is targeting 2024 revenue of $58.5 billion to $61.5 billion, below the $62.66 billion that analysts surveyed by FactSet expected. The company is targeting revenue of $58 billion to $61 billion for this year.
Pfizer said it expects about $8 billion in revenue next year from its Covid-19 vaccine and its Paxlovid treatment for Covid. The company expects those products to contribute about $12.5 billion in revenue this year.
Shares of Pfizer dropped more than 8% to $26.24 in premarket trading. Shares were already down more than 44% this year.
Pfizer expects operational revenue, which excludes contributions from Covid-related products and includes the expected impact from the company's takeover of biotech cancer specialist Seagen, to grow by 8% to 10% in 2024.
The company also said it is targeting adjusted earnings in 2024 of $2.05 a share to $2.25 a share, below the $3.17 a share that analysts surveyed by FactSet expected.
Pfizer will hold a call with executives at 8:30 a.m. ET.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
December 13, 2023 07:26 ET (12:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
